We find new uses for known drugs that are safe in humans, and advance the drugs to proof-of-concept. We also partner with pharma research groups to identify off-target effects underlying drug toxicity.
SeaChange was founded in 2009 by John Irwin, Michael Keiser, and Brian Shoichet out of UCSF, with advice from the QB3 California Institute for Quantitative Biosciences. Generous translational research awards from the Rogers Family Foundation to the Shoichet laboratory in 2009 and 2010 supported commercial development of SEA technology.
John Irwin is Adjunct Associate Professor in the Department of Pharmaceutical Chemistry at UC San Francisco. He works together with Brian Shoichet on methods to discover new reagents for biological targets using target- and ligand-based methods. He applies these methods to various projects, and particiates in numerous collaborations. John develops the ZINC database of commercially available compounds for virtual screening and the DUD-E database for benchmarking virtual screening methods. His most recent product is DOCK Blaster, a free virtual screening service that aims to make docking as reliable and easy to use - if not nearly as fast - as BLAST.
Michael Keiser completed a bioinformatics Ph.D. in 2009 at UC San Francisco as a National Science Foundation Fellow, where he developed techniques to relate proteins based on the statistical similarity of their ligands. He also holds B.Sc., B.A., and M.A. degrees from Stanford University. Michael investigates drug polypharmacology and the prediction of drug off-target activities.
Brian Shoichet received a B.Sc. in Chemistry and a B.Sc. in History in 1985, from MIT. He received his Ph.D. for work with Tack Kuntz on molecular docking in 1991, from UCSF. Shoichet's postdoctoral research was largely experimental, focusing on protein structure and stability with Brian Matthews at the Institute of Molecular Biology in Eugene, Oregon, as a Damon Runyon Fellow. Shoichet joined the faculty at Northwestern University in the Dept. of Molecular Pharmacology & Biological Chemistry as an Assistant Professor in 1996. He was promoted to a tenured Associate Professor in 2002 and recruited back to UCSF, where he is now a Professor in the Department of Pharmaceutical Chemistry. Research in the Shoichet Lab uses computational and experimental techniques to investigate enzyme structure, function, stability and inhibition, and the links among them.
Nick Hodge received a Ph.D. in Organic and Analytical Chemistry from Cornell University. He has held senior leadership positions at DuPont Merck, Caliper Technologies, Amphora Discovery (founder) and Ruga. Inventions from his corporate R&D labs include drugs for human clinical trials in several therapeutic areas, computational methods for drug design, and biological screening technology. Nick has extensive experience in the conception and execution of platform drug discovery startups, including commercialization strategy, fund-raising, business development, sales and management.
Michael Mysinger has a multi-disciplinary background including masters degrees in Chemical Engineering and Computer Science as a Computation Sciences Graduate Fellow at Stanford University. A perennial problem solver, he used quantum chemistry to create ADME and Toxicity models at Camitro and ArQule. He completed his Ph.D. in Pharmaceutical Sciences with Brian Shoichet at UCSF in 2012, studying ligand desolation in molecular docking and how to quantify its performance on large datasets.